Published

Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD)

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Brain Sciences
Date: 2026-03-26
Source: Crossref
DOI: 10.3390/brainsci16040358
PubMed: 42041769

Authors

Skalski Piotr Pękacka-Falkowska Katarzyna Pluto-Prądzyńska Agnieszka Owecki Michał K.

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Addiction End-of-Life Distress Clinical Trial Randomized Controlled Trial Systematic Review Review Article Treatment-Resistant Depression Randomized Controlled Trial

Citation graph

40 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

10.2147/dddt.s443177 10.3390/ph14100985 10.1016/j.drudis.2024.104255 10.1186/s40345-022-00265-5 10.9758/cpn.24.1180 10.1136/bmj-2023-078607 10.1186/s12909-024-06141-3 10.1177/00048674241240597 10.3389/fnins.2024.1420601 10.1097/aln.0000000000004673 10.1007/s40263-024-01101-3 10.1007/s13670-023-00383-7

Indexed papers citing this DOI

Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD)2026-03-26

Related papers

Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary clinical trials · 2022-12-01 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28 A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-ControlClinicalTrials.gov · 2026-05-04 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderClinicalTrials.gov · 2025-08-19